The Global Analgesics Market 2009-2024
Where will the main commercial opportunities lie in the treatment of pain from the present onwards? Our new pharma report explains in depth, giving you the answers that you require.
There remain many unmet therapeutic needs in the treatment of pain, as well as high demand for analgesic treatments worldwide. For several types of pain, including conditions such as diabetic neuropathy and sciatica, there are currently few treatments. Furthermore, the pain sector is associated with side effects. Novel compounds that demonstrate improved safety profiles - combined with high efficacies - have the potential to gain significant market shares from 2009 onwards. At the same time, high regulatory hurdles - in particular those following the Vioxx withdrawal - could restrict market entry. Nevertheless, there remain high potential revenues to be made in this sector from 2009 to 2024, as our new report explains.
Continued high prevalence of pain worldwide, driven by an increase in the many disorders with pain as a symptom, drives the market. Furthermore, intensive R&D - with a solid current pipeline - will make the analgesics market dynamic and commercially promising in the years ahead. There is also rapidly-increasing demand for pain treatments in developing countries. The Global Analgesics Market 2009-2024 – explains how this market will develop, and where the main opportunities will lie during our forecast period.
This report addresses the following therapeutic categories in detail:
- Non-narcotics and anti-pyretics
- Narcotics
- Anti-rheumatic drugs
- Anti-migraine drugs
- Anti-epileptic drugs
- Local anaesthetics.
The Global Analgesics Market 2009-2024 provides detailed forecasts for all six categories, as well as for individual products in each category. What types of therapeutic agents are likely to enter the market from 2009 onwards, and will they hold the potential to dominate? Where do the main opportunities lie, and what are the principal threats in this market area? This report will provide you with the analytical information that you need to understand current trends and future directions in the global analgesics market. We discuss prospects for the following products in detail (by category):
- Non-narcotics and anti-pyretics
- Tylenol
- Advil
- Aspirin Bayer
- Panadol - Narcotics
- Oxycontin
- Duragesic
- Fentanyl Myla - Anti-rheumatic drugs
- Celebrex
- Voltaren - Anti-migraine drugs
- Imigran
- Maxalt - Anti-epileptic drugs
- Lyrica - Local anaesthetics
- Lidoderm
Novel therapeutics and other developments - such as Rx/Dx strategies, monoclonal antibodies and anti-abuse technologies - are included in the pipeline sections of this report.
Comprehensive analysis of the market area
The Global Analgesics Market 2009-2024 examines this market sector critically, through a comprehensive review of information sources, including consultations with relevant experts. There are over 60+ tables and figures plus comprehensive expert interviews. This report provides detailed sales forecasts, discussions of pipeline developments and relevant commercial drivers and restraints. Sources used include commercial databases, industry news, published reports, policy documents and economic research. Importantly, we apply rigorous financial forecasting, qualitative analyses and the assessments of unmet needs. The result is a comprehensive market- and industry-centred report with detailed analysis and informed opinion to benefit your work.
Why you should buy The Global Analgesics Market 2009-2024
In this report you will receive the following benefits, in particular:
- You will assess the current market for analgesic therapeutics
- You will review the overall analgesic therapeutics market, including a global sales forecast for 2009 to 2024
- You will receive sales forecasts for analgesic submarkets from 2009 to 2024, with detailed discussions
- You will receive sales forecasts for leading products from 2009 to 2024, with detailed discussions of market potential and competition
- You will receive sales forecasts for leading geographical markets from 2009 to 2024, with discussions
- You will examine commercial drivers and restraints in depth
- You will discover the most-exciting pipeline developments in the sector, with informed commentary to give you foresight
- You will discover expert opinions from our original survey of the sector, with full interview transcripts provided.
Table of Contents
1. Executive Summary
- 1.1 Aims of This Report
- 1.2 Chapter Breakdown
2. Introduction - Definition of Pain
- 2.1 Physiology of Pain
- 2.1.1 Signal Transmission
- 2.1.2 Endogenous Analgesics
- 2.2 Social and Financial Impact of Pain
- 2.3 Classification and Types of Pain
- 2.3.1 Acute Pain and Chronic Pain
- 2.4 Nociceptive pain
- 2.5 Neuropathic Pain
- 2.6 Psychogenic Pain
- 2.7 Treatment Options
- 2.7.1 Non-Steroidal Anti-Inflammatory Drugs (NSAIDS) and Para-acetylaminophenol
- 2.7.2 Opioids
- 2.7.3 Tricyclic Antidepressants and Anticonvulsants
- 2.8 Defining the Severity of Pain
3. Introduction - The OTC Factor
- 3.1 Key Features of OTC Pharmaceuticals
- 3.2 OTC Switching
- 3.3 OTC Regulation
- 3.4 The OTC Analgesics Market
- 3.4.1 Systemic Analgesics
- 3.4.2 External Analgesics
4. The Global Analgesics Market 2009-2024
- 4.1 Analysis of the Current Market
- 4.1.1 Leading Categories in the Analgesics Market
- 4.1.2 Blockbusters in the Analgesics Market
- 4.2 Forecast for the Global Analgesics Market 2009-2024
- 4.3 Assessment of the OTC Proportion of the Market
- 4.4 Concluding Remarks
5. The Non-Narcotics and Anti-Pyretics Market 2009-2024
- 5.1 Analysis of the Current Market
- 5.2 Forecast for the Non-Narcotics and Anti-Pyretics Market 2009-2024
- 5.3 Tylenol
- 5.3.1 Tylenol Sales Forecast 2009-2024
- 5.3.2 A Billion Dollar OTC Brand
- 5.4 Advil
- 5.4.1 Advil Sales Forecast 2009-2024
- 5.5 Aspirin Bayer
- 5.5.1 Aspirin Bayer Sales Forecast 2009-2024
- 5.6 Panadol
- 5.6.1 Panadol Sales Forecast 2009-2024
- 5.6.2 Targeting Emerging Markets
- 5.7 Concluding Remarks
6. The General Narcotics Market 2009-2024
- 6.1 Analysis of the Current Market
- 6.2 Forecast for the Narcotics Market 2009-2024
- 6.3 Oxycontin
- 6.3.1 Patent Issues
- 6.3.2 Controversies
- 6.4 Duragesic
- 6.4.1 Safety Issues and Risk Management Plans
- 6.5 Fentanyl Myla
- 6.5.1 Competition and Safety Concerns
- 6.6 Concluding Remarks
7. The Anti-Rheumatics Pain Relief Market 2009-2024
- 7.1 Analysis of the Current Market
- 7.2 Forecast for the Anti-Rheumatics Pain Relief Market 2009-2024
- 7.2.1 Safety Issues for COX-2 Inhibitors
- 7.3 Celebrex
- 7.4 Voltaren
- 7.4.1 Surviving Patent Expiry: An OTC Success Story So Far
- 7.4.2 Growth in Emerging Markets
- 7.5 Concluding Remarks
8. The Anti-Migraine Market 2009-2024
- 8.1 Causes of Migraine
- 8.1.1 Triggers of Migraine Headaches
- 8.1.2 Treatment Options
- 8.2 Analysis of the Current Market
- 8.3 Forecast for the Anti-Migraine Market 2009-2024
- 8.4 Imigran
- 8.5 Maxalt
- 8.6 Competition in the Anti-Migraine Market
- 8.7 Future Directions and Concluding Remarks
9. The Anti-Epilepsy Market 2009-2024
- 9.1 The Physiology and Treatment of Epilepsy
- 9.2 Analysis of the Current Market
- 9.3 Forecast for the Anti-Epilepsy Market 2009-2024
- 9.4 Lyrica
- 9.5 Concluding Remarks
10. The Local Anaesthetics Market 2009-2024
- 10.1 Analysis of the Local Anaesthetics Market
- 10.2 Forecast for the Local Anaesthetics Market 2009-2024
- 10.3 Lidoderm
- 10.3.1 Competition for Lidoderm
- 10.4 Concluding Remarks
11. SWOT Analysis
- 11.1 Market Drivers
- 11.1.1 Personalised Therapy
- 11.1.2 Increasing Prevalence
- 11.1.3 Products with Several Indications
- 11.2 Market Restraints
- 11.2.1 Effects of the Vioxx Issue
- 11.2.2 Reimbursement Issues and the Cost of Healthcare
- 11.2.3 Side Effects Limit the Narcotics Market
- 11.2.4 Under-Treatment of Pain
- 11.3 Concluding Remarks
12. Pipeline and Novel Products
- 12.1 Tanezumab
- 12.2 Ralfinamide
- 12.3 Nucynta (Tapentadol)
- 12.4 Abuse-Resistant Products
- 12.4.1 Remoxy
- 12.4.2 Embeda
- 12.5 COX-Inhibiting Nitric Oxide Donators
- 12.5.1 Naproxcinod
- 12.6 Improvements in Drug Delivery
- 12.6.1 Onsolis
- 12.6.2 Rapinyl/Abstral
- 12.6.3 Eladur
- 12.7 Cannabinoids - An Alternative to Opioids?
- 12.7.1 Sativex
- 12.8 Rx/Dx Tests
13. Geographical Breakdown of the Market
- 13.1 USA
- 13.2 The Mature European Market
- 13.3 Key Emerging Markets
- 13.3.1 China and India
- 13.3.2 Brazil
- 13.3.3 Russia and Eastern Europe
- 13.4 Concluding Remarks
14. Expert Opinions
- 14.1 Interview with Dr Anastasia Liapi (Astellas Pharma Europe)
- 14.1.1 On Assessing the Commercial Value of Novel Pain Therapies
- 14.1.2 On the Hurdles That Face New Launches in the Pain Market
- 14.1.3 On Geographical Differences
- 14.2 Interview with Dr William Schmidt (NorthStar Consulting LLC)
- 14.2.1 On the Growth of the Pain Market
- 14.2.2 On New Targets in Pain Management
- 14.2.3 On Unmet Needs in the Pain Market
- 14.2.4 On Regulatory Hurdles in the Post-Vioxx Era
- 14.2.5 On the Future of COX-2 Inhibitors
15. Conclusions
- 15.1 Growth
- 15.2 Market Dominance
- 15.3 Geographical Opportunities
- 15.4 OTC Issues
List of Tables
- Table 3.1 Leading OTC Categories, Sales ($bn) and Market Share (%) 2008
- Table 4.1 Leading Categories in the Analgesics Market, Sales ($m) and Market Share (%) 2008
- Table 4.2 Blockbusters in the Analgesics Market, Sales ($m) and Market Share (%) 2008
- Table 4.3 The Global Analgesics Market, Sales ($m), Growth (%) and CAGR (%) 2008-2014, 2019, 2024
- Table 4.4 The OTC and Rx Arms of the Analgesics Market, Sales ($m) and Growth (%) 2008-2014
- Table 5.1 Leading Companies in the Non-Narcotics and Anti-Pyretics Market, Sales ($m) and Market Share (%) 2008
- Table 5.2 The Non-Narcotics and Anti-Pyretics Market, Sales ($m), Growth (%) and CAGR (%) 2008-2014, 2019, 2024
- Table 6.1 Common Opioid Narcotics
- Table 6.2 Geographical Breakdown of the Narcotics Market, Sales ($m) and Market Share (%) 2008
- Table 6.3 Leading Companies in the Narcotics Market, Sales ($m) and Market Share (%) 2008
- Table 6.4 The Narcotics Market, Sales ($m), Growth (%) and CAGR (%) 2008-2014, 2019, 2024
- Table 7.1 The Anti-Rheumatics Pain Relief Market, Sales ($m), Growth (%) and CAGR (%) 2008-2014, 2019, 2024
- Table 8.1 Migraine Triggers
- Table 8.2 Leading Companies in the Anti-Migraine Market, Sales ($m) and Market Share (%) 2008
- Table 8.3 The Anti-Migraine Market, Sales ($m), Growth (%) and CAGR (%) 2008-2014, 2019, 2024
- Table 8.4 Patent Expiries in the Anti-Migraine Market
- Table 9.1 The Anti-Epileptics Pain Relief Market, Sales ($m), Growth (%) and CAGR (%) 2008-2014, 2019, 2024
- Table 10.1 Top-Selling Local Anaesthetics ($m) 2008
- Table 10.2 Leading Companies in the Local Anaesthetics Market, Sales ($m) and Market Share (%) 2008
- Table 10.3 Geographical Breakdown of the Local Anaesthetics Market, Sales ($m) and Market Share (%) 2008
- Table 10.4 The Local Anaesthetics Market, Sales ($m), Growth (%) and CAGR (%) 2008-2014, 2019, 2024
- Table 11.1 SWOT Analysis of the Global Analgesics Market 2009-2024
- Table 13.1 Geographical Breakdown of the Analgesics Market, Sales ($m), Market Share (%) and CAGR (%) 2008-2014, 2019, 2024
List of Figures
- Figure 3.1 Leading OTC Categories, Market Share (%) 2008
- Figure 4.1 Leading Categories in the Analgesics Market, Market Share (%) 2008
- Figure 4.2 Blockbusters in the Analgesics Market, Market Share (%) 2008
- Figure 4.3 The Global Analgesics Market, Sales ($m) 2008-2024
- Figure 4.4 The OTC and Rx Arms of the Analgesics Market, Market Share (%) 2008-2014
- Figure 5.1 Leading Companies in the Non-Narcotics and Anti-Pyretics Market, Market Share (%) 2008
- Figure 5.2 Non-Narcotics and Anti-Pyretics Sales ($m) 2008-2024
- Figure 5.3 Tylenol Sales ($m) 2008-2024
- Figure 5.4 Advil Sales ($m) 2008-2024
- Figure 5.5 Aspirin Bayer Sales ($m) 2008-2024
- Figure 5.6 Panadol Sales ($m) 2008-2024
- Figure 6.1 Geographical Breakdown of the Narcotics Market, Market Share (%) 2008
- Figure 6.2 Leading Companies in the Narcotics Market, Market Share (%) 2008
- Figure 6.3 Narcotics Sales ($m) 2008-2024
- Figure 6.4 Oxycontin Sales ($m) 2008-2024
- Figure 6.5 Duragesic Sales ($m) 2008-2024
- Figure 6.6 Fentanyl Sales ($m) 2008-2024
- Figure 7.1 Anti-Rheumatics Pain Relief Sales ($m) 2008-2024
- Figure 7.2 Celebrex Sales ($m) 2008-2024
- Figure 7.3 Voltaren Sales ($m) 2008-2024
- Figure 7.4 Celebrex, Voltaren and Other Anti-Rheumatics, Sales ($m) 2008, 2014, 2019 and 2024
- Figure 8.1 Leading Companies in the Anti-Migraine Market, Market Share (%) 2008
- Figure 8.2 Anti-Migraine Sales ($m) 2008-2024
- Figure 8.3 Imigran Sales ($m) 2008-2024
- Figure 8.4 Maxalt Sales ($m) 2008-2024
- Figure 9.1 Anti-Epileptics Pain Relief Sales ($m) 2008-2024
- Figure 9.2 Lyrica Sales ($m) 2008-2024
- Figure 9.3 Lyrica and Other Anti-Epileptics, Sales ($m) 2008, 2014, 2019 and 2024
- Figure 10.1 Leading Companies in the Local Anaesthetics Market, Market Share (%) 2008
- Figure 10.2 Geographical Breakdown of the Local Anaesthetics Market, Market Share (%) 2008
- Figure 10.3 Local Anaesthetics Sales ($m) 2008-2024
- Figure 10.4 Lidoderm Sales ($m) 2009-2024
- Figure 10.5 Lidoderm and Other Local Anaesthetics, Sales ($m) 2008, 2014, 2019 and 2024
- Figure 13.1 Geographical Breakdown of the Analgesics Market by Country, Sales ($m) 2009, 2014, 2019, 2024
- Figure 13.2 Geographical Breakdown of the Analgesics Market, Market Share (%) 2008
- Figure 13.3 Geographical Breakdown of the Analgesics Market, Market Share (%) 2024
- Figure 13.4 European Analgesics Market, Sales ($m) 2009, 2014, 2019 and 2024
- Figure 13.5 Emerging Analgesics Markets, Sales ($m) 2009, 2014, 2019 and 2024
- Figure 13.6 Latin America Analgesics Market, Sales ($m) 2009, 2014, 2019 and 2024
- Figure 13.7 Geographical Breakdown of the Analgesics Market by Region, Sales ($m) 2009, 2014, 2019, 2024
Other users found this report page using the following search terms: pain analgesia analgesic hyperalgesic neuropathy neuropathic market share sales analgesic analgesics global tapentadol migraine 2009 globalanalgesicsmarket
If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.
Refund and Cancellation Policy: The descriptions of the products and services sold on LeadDiscovery.co.uk are as complete and accurate as possible, and customers are encouraged to read all available information about a product before placing an order. Due to the nature of the information being sold, orders for reports cannot be canceled.